New Jersey Hematology Oncology Associates, LLC

Brick, New Jersey 08724-3009

0 studies enrolling now · 7 studies all time

What they study most

Advanced Unresectable or Metastatic Solid Malignancy, Hodgkin Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndrome, Myelofibrosis, Non-small Cell Lung Cancer, Polycythemia Vera, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis, Thrombocythemia

Studies at this site

• A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer — Completed
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) — Completed
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma — Stopped early
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response — Completed